Discovers and develops medicines for rare diseases. Commercializes treatments for autoimmune conditions. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 32% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $210.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 51× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 9% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 32% a year on average.
The company’s market value is 51 times its annual profit. Even a small disappointment could hit the price hard.
The price action doesn’t yet back an upward turn. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.